Health technology assessments (HTAs) are the foundation of evidence-based decision-making for reimbursement, and coverage of medicines and medical technologies. Traditionally, the process has been heavily anchored in evidence from randomized controlled trials (RCTs), assessed at the time of market entry. However, healthcare systems have been evolving and are increasingly shifting toward a lifecycle approach to HTA. This means that the evaluation of a technology does not end with the initial reimbursement decision but continues throughout its use in clinical practice. This is where HTA reassessments (HTARs) come into play, and where real-world data (RWD) are progressively defining a role.
Why Reassessments Are Needed
Initial HTA decisions are based on the best available evidence at launch, but that evidence might be incomplete. Clinical trials have limited follow-up, narrow eligibility criteria, and controlled settings that do not reflect how technologies perform in everyday care. Once a drug (or device) is used in routine practice, many unanswered questions remain. Do the outcomes seen in trials replicate in broader, more heterogeneous populations? Are there safety signals that only emerge after years of use? Does the technology remain cost-effective once its real-world performance and evolving comparators are considered? These are some of the questions that reassessments seek to answer and how those are addressed may vary.
The German Approach to Reassessment
In Germany, the introduction of a new medicine is controlled by a distinctive regulatory framework that links early market access to systematic benefit evaluation. When a product first enters the market, manufacturers are free to set the price during the initial twelve months. This period, however, is not without scrutiny: the medicine is subject to an early benefit assessment conducted by the Gemeinsamer Bundesausschuss (G-BA), with technical evaluation provided by IQWiG. The assessment is based primarily on the manufacturer’s dossier and available clinical trial data. Its outcome determines the perceived additional benefit of the drug compared to standard of care and forms the basis for subsequent price negotiations with the statutory health insurance system (GKV-Spitzenverband). However, this initial evaluation does not end the process. A formal reassessment, or HTAR, can be triggered under several circumstances. These include the emergence of new evidence—often RWD from registries or post-authorization studies—an extension of the therapeutic indication, or a specific requirement imposed by the G-BA for the manufacturer to deliver additional data by a set deadline. Such triggers are particularly common in oncology and rare diseases, where the evidence at launch is frequently considered immature. The typical trajectory of an HTAR follows a structured sequence. After the initial assessment and price negotiations within the first year, the G-BA may impose conditional evidence requirements. These often take the form of a mandated registry or post-authorization study, with timelines generally extending two to three years to allow sufficient data to accumulate. By year three to five after launch, the manufacturer is expected to submit a reassessment dossier that integrates the newly generated evidence. This evidence may derive from German disease registries, international data sources, or additional clinical studies. Once the reassessment dossier is filed, the G-BA and IQWiG revisit the benefit evaluation. Within six months, the G-BA issues a revised decision on the drug’s added benefit. This decision has direct financial and strategic implications: confirmation of benefit allows maintenance of the negotiated price, while downgrading of benefit often results in substantial price reductions. In cases where the indication has broadened or been restricted, the reimbursement conditions are also recalibrated. Through this cyclical process, the German system ensures that pricing and reimbursement remain closely tied to evolving evidence, with RWD playing an increasingly central role in sustaining or challenging the initial value proposition of new medicines.
RWD as the Evidence Strength for HTARs
The foundation of any reassessment lies in the ability to generate new and contextually relevant evidence and on the ability to capture high-quality evidence beyond the trial environment. RWD has become a key element of this process, extending the evidence generated with RCTs. Sources of RWD—ranging from electronic health records and insurance claims to disease registries, patient-reported outcomes, and increasingly, data from connected devices—enable a longitudinal and population-level understanding of how technologies perform once introduced into routine care.
For safety reassessments, RWD allows for the detection of adverse events and treatment patterns that may only emerge after years of widespread use. Pharmacovigilance networks and disease registries can capture these patterns at scale, identifying population subgroups that might be at higher risk or benefit.
For effectiveness, linked health data provide a window into whether the clinical benefits seen in trials persist when patients are older, sicker, or less adherent than those in the study population. Moreover, as new comparators enter the market, RWD enables the continuous benchmarking of outcomes in an evolving therapeutic landscape.
For economic reassessments, real-world utilization and cost data bring reevaluations closer to the realities of healthcare spending. They provide dynamic inputs for cost-effectiveness and budget impact models, reflecting actual treatment pathways, dosing adjustments, and resource use. In this sense, RWD not only complements the evidence from trials—it anchors HTARs in the lived experience of healthcare systems and patients.
From Episodic Evaluation to Continuous Monitoring
Historically, reassessments have been reactive, triggered by a signal, a new competitor, or the expiration of a managed entry agreement. However, the practical and systematic integration of RWD means that reassessments can move away from reactive, ad hoc processes triggered by a safety signal or competitor launch, toward more proactive, structured monitoring as the availability and quality of RWD improve, many health systems are shifting toward more systematic, ongoing forms of evidence generation and monitoring. The goal is to transition from episodic evaluation to a model of continuous learning and adaptation. This is evident in countries like Germany, where reassessments are tied to price renegotiations, or in Canada, where CADTH has piloted reassessments based on registry data. The challenge remains in ensuring that RWD infrastructures are designed to feed into these processes: standardized, interoperable, and collected under transparent governance frameworks. When these conditions are met, reassessment ceases to be a bureaucratic requirement—it becomes a mechanism for ongoing accountability and innovation management.
Methodological and Operational Challenges
Despite the promise of RWD-enabled reassessments, several methodological and operational challenges persist. The quality and completeness of RWD remain uneven across sources and countries. Differences in coding practices, data capture systems, and outcome definitions can introduce noise or bias. As a result, translating RWD into regulatory- or payer-grade evidence requires rigorous design principles and analytical discipline.
Advanced methods are increasingly used to approximate the rigor of randomized studies. However, methodological sophistication alone is not enough; transparency about data limitations remain essential for credibility. Regulators and HTA bodies must also align on acceptable evidence standards for reassessments, which today vary widely across jurisdictions.
Operationally, HTARs demand coordinated effort across stakeholders. Clinicians and healthcare institutions must collect consistent data at the point of care. Patients, through registries and digital platforms, contribute valuable outcome information and lived experience. Industry partners often bear responsibility for establishing or funding post-authorization data collection frameworks. And payers and regulators must define the evidence thresholds that determine whether a therapy’s reimbursement or price will change. This multidimensional collaboration is complex, but it is also the backbone of credible reassessment systems.
Toward a Lifecycle Model of Evidence
The integration of RWD into reassessment processes reflects a larger model shift: from static decision-making at launch to a lifecycle model of evidence. In this new model, approval, reimbursement, and continued market access are no longer single points in time but milestones in an evolving dialogue between evidence and policy.
Conditional approvals and managed entry agreements exemplify this shift. They allow earlier patient access, provided that post-launch data confirm their value and safety. As RWD accumulates, reassessments become checkpoints where decisions are updated, ensuring that payers continue to fund interventions that deliver real benefit. This approach aligns scientific rigor with practical flexibility, balancing innovation incentives with system sustainability.
The lifecycle model also encourages a more integrated relationship between regulators, HTA agencies, and payers. Rather than operating in silos, these entities collaborate around shared evidence plans, ensuring that data collected for regulatory purposes can also inform health technology reassessment. Over time, this alignment could transform the evidence ecosystem, embedding learning and feedback into every stage of a product’s life.
Conclusion
HTA reassessments are gaining prominence as health systems confront the dual pressures of rising costs and accelerating innovation. RWD stands at the center of this evolution, offering the possibility of more accurate, timely, and patient-centered reassessments. The challenge now is less about recognizing the potential of RWD, and more about building the infrastructures, governance, and methodological consensus that will make reassessments both credible and impactful. As payers, regulators, and researchers move toward a lifecycle model of evidence, RWD will not just complement HTA, it will redefine it.
